RATIONALE: Glutathione (GSH) is a key scavenger for cellular free radicals, and patients with bipolar disorder may have lowered GSH levels in plasma and in post-mortem brain tissue. OBJECTIVES: The objective of the current study was to use magnetic resonance spectroscopy (MRS) to measure cortical GSH levels in young people with bipolar disorder to determine if lowered GSH might be a useful biomarker of vulnerability to the illness. METHODS: We studied 13 patients with DSM-IV bipolar disorder and 11 healthy age-matched controls using proton MRS in conjunction with the SPECIAL acquisition technique. Voxels were placed in prefrontal and occipital cortex. All patients were clinically euthymic at the time of study and unmedicated. GSH and other relevant neurometabolites were measured relative to creatinine. RESULTS: There was no difference in GSH levels between bipolar participants and controls in either prefrontal or occipital cortex. Similarly, participants showed no difference from controls in other measured cortical metabolites including γ-aminobutyric acid, glutamate and N-acetylaspartate. CONCLUSIONS: This pilot study suggests that levels of cortical GSH are unlikely to be a useful trait biomarker of bipolar disorder in young people with a history of relatively mild mood instability at an early stage of illness. Lowered GSH levels may be relevant to bipolar pathophysiology in more severely ill patients, particular those with significant current mood disturbance.
RATIONALE: Glutathione (GSH) is a key scavenger for cellular free radicals, and patients with bipolar disorder may have lowered GSH levels in plasma and in post-mortem brain tissue. OBJECTIVES: The objective of the current study was to use magnetic resonance spectroscopy (MRS) to measure cortical GSH levels in young people with bipolar disorder to determine if lowered GSH might be a useful biomarker of vulnerability to the illness. METHODS: We studied 13 patients with DSM-IV bipolar disorder and 11 healthy age-matched controls using proton MRS in conjunction with the SPECIAL acquisition technique. Voxels were placed in prefrontal and occipital cortex. All patients were clinically euthymic at the time of study and unmedicated. GSH and other relevant neurometabolites were measured relative to creatinine. RESULTS: There was no difference in GSH levels between bipolar participants and controls in either prefrontal or occipital cortex. Similarly, participants showed no difference from controls in other measured cortical metabolites including γ-aminobutyric acid, glutamate and N-acetylaspartate. CONCLUSIONS: This pilot study suggests that levels of cortical GSH are unlikely to be a useful trait biomarker of bipolar disorder in young people with a history of relatively mild mood instability at an early stage of illness. Lowered GSH levels may be relevant to bipolar pathophysiology in more severely ill patients, particular those with significant current mood disturbance.
Authors: Jeremy W Gawryluk; Jun-Feng Wang; Ana C Andreazza; Li Shao; Lakshmi N Yatham; L Trevor Young Journal: Int J Neuropsychopharmacol Date: 2011-05-09 Impact factor: 5.176
Authors: Michael Berk; Olivia Dean; Sue M Cotton; Clarissa S Gama; Flavio Kapczinski; Brisa S Fernandes; Kristy Kohlmann; Susan Jeavons; Karen Hewitt; Christine Allwang; Heidi Cobb; Ashley I Bush; Ian Schapkaitz; Seetal Dodd; Gin S Malhi Journal: J Affect Disord Date: 2011-06-29 Impact factor: 4.839
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Harald Scherk; Martin Backens; Thomas Schneider-Axmann; Juliana Usher; Claudia Kemmer; Wolfgang Reith; Peter Falkai; Oliver Gruber Journal: World J Biol Psychiatry Date: 2009 Impact factor: 4.132
Authors: S Andrea Wijtenburg; Jamie Near; Stephanie A Korenic; Frank E Gaston; Hongji Chen; Mark Mikkelsen; Shuo Chen; Peter Kochunov; L Elliot Hong; Laura M Rowland Journal: J Magn Reson Imaging Date: 2018-04-16 Impact factor: 4.813
Authors: Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos Journal: Antioxid Redox Signal Date: 2019-02-01 Impact factor: 8.401
Authors: Daniel F Hermens; Sean N Hatton; Rico S C Lee; Sharon L Naismith; Shantel L Duffy; G Paul Amminger; Manreena Kaur; Elizabeth M Scott; Jim Lagopoulos; Ian B Hickie Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-03-29 Impact factor: 5.270
Authors: Vincent A Magnotta; Jia Xu; Jess G Fiedorowicz; Aislinn Williams; Joseph Shaffer; Gary Christensen; Jeffrey D Long; Eric Taylor; Leela Sathyaputri; Jenny Gringer Richards; Gail Harmata; John Wemmie Journal: J Affect Disord Date: 2022-01-12 Impact factor: 4.839
Authors: Alice M S Durieux; Jamie Horder; M Andreina Mendez; Alice Egerton; Steven C R Williams; C Ellie Wilson; Debbie Spain; Clodagh Murphy; Dene Robertson; Gareth J Barker; Declan G Murphy; Grainne M McAlonan Journal: Autism Res Date: 2015-08-20 Impact factor: 5.216
Authors: Jamie Near; Richard Edden; C John Evans; Raphaël Paquin; Ashley Harris; Peter Jezzard Journal: Magn Reson Med Date: 2014-01-16 Impact factor: 4.668